Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial

Documenti analoghi

• Impact of Anti‐Inflammatory Drug Therapy on the Efficacy of First‐Line Atezolizumab Treatment in Patients With Advanced Non‐Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled Trials
  di: Kazuki Takada, et al.
  Pubblicazione: (2026)
• Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer
  di: Shinkichi Takamori, et al.
  Pubblicazione: (2025)
• Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
  di: Tadashi Nishimura, et al.
  Pubblicazione: (2024)
• Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
  di: Han Li, et al.
  Pubblicazione: (2024)
• Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
  di: Ayako Morita, et al.
  Pubblicazione: (2024)